• Home
  • Search Results
  • PET imaging of disease progression and treatment effects in the experimental autoimmune encephalomyelitis rat model.

PET imaging of disease progression and treatment effects in the experimental autoimmune encephalomyelitis rat model.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2014-06-11)
Daniele de Paula Faria, Maria L H Vlaming, Sjef C V M Copray, Frans Tielen, Herma J A Anthonijsz, Jurgen W A Sijbesma, Carlos A Buchpiguel, Rudi A J O Dierckx, José W A van der Hoorn, Erik F J de Vries

The experimental autoimmune encephalomyelitis model is a model of multiple sclerosis that closely mimics the disease characteristics in humans. The main hallmarks of multiple sclerosis are neuroinflammation (microglia activation, monocyte invasion, and T-cell infiltration) and demyelination. PET imaging may be a useful noninvasive technique for monitoring disease progression and drug treatment efficacy in vivo. Experimental autoimmune encephalomyelitis was induced by myelin-oligodendrocyte glycoprotein immunization in female Dark Agouti rats. Experimental autoimmune encephalomyelitis rats were imaged at baseline and at days 6, 11, 15, and 19 after immunization to monitor monocyte and microglia activation ((11)C-PK11195) and demyelination ((11)C-MeDAS) during normal disease progression and during treatment with dexamethasone. (11)C-PK11195 PET detected activation of microglia and monocytes in the brain stem and spinal cord during disease progression. The uptake of (11)C-PK11195 was elevated in dexamethasone-treated animals that had shown mild clinical symptoms that had resolved at the time of imaging. Demyelination was not detected by (11)C-MeDAS PET, probably because of the small size of the lesions (average, 0.13 mm). PET imaging of neuroinflammation can be used to monitor disease progression and the consequences of treatment in the experimental autoimmune encephalomyelitis rat model. PET imaging was more sensitive than clinical symptoms for detecting inflammatory changes in the central nervous system.

Product Number
Product Description

Dexamethasone 21-acetate, ≥99%
Dexamethasone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material
Dexamethasone acetate, European Pharmacopoeia (EP) Reference Standard
Dexamethasone acetate, United States Pharmacopeia (USP) Reference Standard
Dexamethasone 21-acetate, VETRANAL®, analytical standard

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.